Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.

NCT Number	NCT07225972
Lead Sponsor	New York Medical College
Conditions	CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Enrollment	69 participants
Start Date	2026-12-01
Primary Completion	2031-12-01 (estimated)
Study Completion	2032-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-10